Teijin Pharma
As of the edition of 20 October 2026, Teijin Pharma runs 8 drugs, 7 of them marketed; it is on route A at 0 targets and on route B at 6 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 7 |
| Status not established | 1 |
| Total | 8 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Alendronic acid | none listed | 3 |
| Lanreotide | none listed | 6 |
| Febuxostat | none listed | 2 |
| Ciclesonide | none listed | 2 |
| Abaloparatide | none listed | 3 |
| Palopegteriparatide | Ends 2037 (patent) | 3 |
| Elapegademase | Ends 2030 (computed from the first US licence) | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 6 targets.
All 6 rows on route A or B
In the product6 company-target rows on route A or B; 3 are not shown here, and no score is.
See all 6 targets where Teijin Pharma needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Heart and blood vessels: 1 trials led
- Nervous system: 1 trials led